Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10071021rdf:typepubmed:Citationlld:pubmed
pubmed-article:10071021lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:10071021lifeskim:mentionsumls-concept:C0026336lld:lifeskim
pubmed-article:10071021lifeskim:mentionsumls-concept:C0450127lld:lifeskim
pubmed-article:10071021lifeskim:mentionsumls-concept:C1882727lld:lifeskim
pubmed-article:10071021lifeskim:mentionsumls-concept:C0332161lld:lifeskim
pubmed-article:10071021lifeskim:mentionsumls-concept:C0035015lld:lifeskim
pubmed-article:10071021lifeskim:mentionsumls-concept:C0333361lld:lifeskim
pubmed-article:10071021lifeskim:mentionsumls-concept:C0003438lld:lifeskim
pubmed-article:10071021lifeskim:mentionsumls-concept:C1882923lld:lifeskim
pubmed-article:10071021lifeskim:mentionsumls-concept:C1548437lld:lifeskim
pubmed-article:10071021lifeskim:mentionsumls-concept:C0205250lld:lifeskim
pubmed-article:10071021lifeskim:mentionsumls-concept:C0549193lld:lifeskim
pubmed-article:10071021pubmed:issue4lld:pubmed
pubmed-article:10071021pubmed:dateCreated1999-3-16lld:pubmed
pubmed-article:10071021pubmed:abstractTextAntithrombin III (AT-III) is an antithrombotic agent with known anti-inflammatory properties that is also known to attenuate acute inflammation, prevent ischemia-reperfusion injury, and disseminated intravascular coagulation (DIC) associated with sepsis and endotoxemia. Here, we examined the ability of AT-III to modify parameters of acute inflammation in a highly histoincompatible model of rat lung allograft rejection (AR).lld:pubmed
pubmed-article:10071021pubmed:languageenglld:pubmed
pubmed-article:10071021pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10071021pubmed:citationSubsetIMlld:pubmed
pubmed-article:10071021pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10071021pubmed:statusMEDLINElld:pubmed
pubmed-article:10071021pubmed:monthFeblld:pubmed
pubmed-article:10071021pubmed:issn0041-1337lld:pubmed
pubmed-article:10071021pubmed:authorpubmed-author:OkadaYYlld:pubmed
pubmed-article:10071021pubmed:authorpubmed-author:ToyodaMMlld:pubmed
pubmed-article:10071021pubmed:authorpubmed-author:MarchevskyA...lld:pubmed
pubmed-article:10071021pubmed:authorpubmed-author:JordanS CSClld:pubmed
pubmed-article:10071021pubmed:authorpubmed-author:MatloffJ MJMlld:pubmed
pubmed-article:10071021pubmed:authorpubmed-author:ZuoX JXJlld:pubmed
pubmed-article:10071021pubmed:authorpubmed-author:NicolaidouEElld:pubmed
pubmed-article:10071021pubmed:issnTypePrintlld:pubmed
pubmed-article:10071021pubmed:day27lld:pubmed
pubmed-article:10071021pubmed:volume67lld:pubmed
pubmed-article:10071021pubmed:ownerNLMlld:pubmed
pubmed-article:10071021pubmed:authorsCompleteYlld:pubmed
pubmed-article:10071021pubmed:pagination526-8lld:pubmed
pubmed-article:10071021pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:10071021pubmed:meshHeadingpubmed-meshheading:10071021...lld:pubmed
pubmed-article:10071021pubmed:meshHeadingpubmed-meshheading:10071021...lld:pubmed
pubmed-article:10071021pubmed:meshHeadingpubmed-meshheading:10071021...lld:pubmed
pubmed-article:10071021pubmed:meshHeadingpubmed-meshheading:10071021...lld:pubmed
pubmed-article:10071021pubmed:meshHeadingpubmed-meshheading:10071021...lld:pubmed
pubmed-article:10071021pubmed:meshHeadingpubmed-meshheading:10071021...lld:pubmed
pubmed-article:10071021pubmed:meshHeadingpubmed-meshheading:10071021...lld:pubmed
pubmed-article:10071021pubmed:meshHeadingpubmed-meshheading:10071021...lld:pubmed
pubmed-article:10071021pubmed:meshHeadingpubmed-meshheading:10071021...lld:pubmed
pubmed-article:10071021pubmed:meshHeadingpubmed-meshheading:10071021...lld:pubmed
pubmed-article:10071021pubmed:meshHeadingpubmed-meshheading:10071021...lld:pubmed
pubmed-article:10071021pubmed:meshHeadingpubmed-meshheading:10071021...lld:pubmed
pubmed-article:10071021pubmed:meshHeadingpubmed-meshheading:10071021...lld:pubmed
pubmed-article:10071021pubmed:meshHeadingpubmed-meshheading:10071021...lld:pubmed
pubmed-article:10071021pubmed:year1999lld:pubmed
pubmed-article:10071021pubmed:articleTitleAntithrombin III treatment improves parameters of acute inflammation in a highly histoincompatible model of rat lung allograft rejection.lld:pubmed
pubmed-article:10071021pubmed:affiliationDepartment of Cardiothoracic Surgery, The Cedars-Sinai Medical Center Burns and Allen Research Institute, UCLA School of Medicine, Los Angeles, California 90048, USA.lld:pubmed
pubmed-article:10071021pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10071021lld:pubmed